Searches , social queries for DAVID E-NICHOLS
Search references for DAVID E-NICHOLS. Phrases containing DAVID E-NICHOLS
See searches and references containing DAVID E-NICHOLS!
Search references for DAVID E-NICHOLS. Phrases containing DAVID E-NICHOLS
See searches and references containing DAVID E-NICHOLS!DAVID E-NICHOLS
American pharmacologist and medicinal chemist (born 1944)
Machine Purdue University - Nichols Erowid Character Vaults: David E. Nichols Heffter Research Institute LSD Neuroscience Nichols's lecture in Psychedelic
David_E._Nichols
Topics referred to by the same term
officer David E. Nichols (born 1944), American pharmacologist and medicinal chemist David Eccles Nichols (1873–1962), violist David H. Nichols (1826–1900)
David_Nichols
the TWEETIO psychedelics David E. Nichols – developed numerous psychedelic phenethylamines, tryptamines, and lysergamides David E. Olson – founder of Delix
List_of_psychedelic_chemists
Class of psychoactive drugs that produce empathic experiences
psychologist and psychopharmacologist, and David Nichols, a professor of medicinal chemistry at Purdue University. Nichols subsequently rejected the term and
Entactogen
American pharmacologist
including giving them psychedelics. Nichols is the son of famous psychedelic chemist David E. Nichols. Charles Nichols is a professor and researcher at Louisiana
Charles_D._Nichols
2010 American film
features Alexander Shulgin, Ann Shulgin, David E. Nichols, Roland Griffiths, Solomon H. Snyder, William Fantegrossi, John E. Mendelson, Ted Shulgin, Robert "Bob"
Dirty Pictures (2010 documentary)
Dirty_Pictures_(2010_documentary)
Swiss chemist (1906–2008)
(2011) History of LSD Drug design Psychedelic therapy James Fadiman David E. Nichols Alexander Shulgin Owsley Stanley List of psychedelic chemists Hofmann
Albert_Hofmann
American medicinal chemist
Purdue University in 1981. He worked in the lab of psychedelic chemist David E. Nichols studying psychedelics, entactogens, and related drugs, first completing
Robert_Oberlender
American actor
Orleans, Louisiana, Nichols graduated from McDonogh 35 College Preparatory Charter High School and the University of New Orleans. Nichols is also known for
Lance_E._Nichols
Class of drugs
Nichols, David E. (2018). "Chemistry and Structure–Activity Relationships of Psychedelics". In Halberstadt, Adam L.; Vollenweider, Franz X.; Nichols,
Hallucinogen
Surname list
David C. Nichols (born 1950), American naval officer David E. Nichols (born 1944), American pharmacologist and medicinal chemist David Eccles Nichols
Nichols_(surname)
Psychedelic drug
and its chemical synthesis was improved by David E. Nichols and colleagues in 1999. It was suggested by Nichols as a more economical and accessible alternative
4-AcO-DMT
Psychoactive drug, often called ecstasy
Nichols DE, Oberlender R (1989). "Structure-activity relationships of MDMA-like substances". NIDA Research Monograph. 94: 1–29. PMID 2575223. Nichols
MDMA
American judge (1917–1997)
David Arthur Nichols (August 6, 1917 – June 21, 1997), of Lincolnville, Maine, was a justice of the Maine Supreme Judicial Court from May 24, 1977, to
David_A._Nichols
Psychedelic drug
in animals. LSZ was first described in the scientific literature by David E. Nichols and colleagues in 2002. It was developed as a tool for studying psychedelic
LSZ
Pharmaceutical compound
family related to 3,4-methylenedioxyamphetamine (MDA) developed by David E. Nichols and colleagues. It is considerably less potent than MDA as an MRA in
3,4-Isopropylidenedioxyamphetamine
3,4-Isopropylidenedioxyamphetamine
Altered state of consciousness
report Nichols, David E. (2016). "Psychedelics". Pharmacological Reviews. 68: 264–355. doi:10.1124/pr.115.011478. PMC 4813425. Geyer, Mark A.; Nichols, David
Psychedelic_experience
Chemical compound
substituted amphetamine class developed in the 1990s by a team led by David E. Nichols, an American pharmacologist and medical chemist, at Purdue University
4-Methylthioamphetamine
Psychedelic drug
Bromo-DragonFLY was first described in the scientific literature by David E. Nichols and colleagues in 1998. It was encountered as a novel designer drug
Bromo-DragonFLY
Pharmaceutical compound
in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1985. Its effects in humans were first described
PHENETH-LAD
English violist (1873–1962)
Aberdeen) was a violist, member of the Verbrugghen String Quartet and the Fellowes String Quartet. "Nichols, David. E. 1873-1962 | Reid Concerts". v t e
David_Eccles_Nichols
Pharmaceutical compound
described in the scientific literature by Robert Oberlender of the lab of David E. Nichols at Purdue University by 1989. The most potent diastereomer of LA-3Cl-SB
LA-3Cl-SB
Chemical compound
of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a less neurotoxic and highly selective
MMAI
Nonprofit organization
the wider scientific community. The institute was founded in 1993 by David E. Nichols. Co-founders included Mark Geyer, Ph.D., Charles Grob, M.D. Dennis
Heffter_Research_Institute
Pharmaceutical compound
been added to the phenyl ring (i.e., the A ring of LSD). The synthesis of UCD0120-2C-D was attempted by David E. Nichols in his PhD thesis in 1973, though
UCD0120-2C-D
Pharmaceutical compound
lysergic acid diethylamide (LSD). It was developed by psychedelic chemist David E. Nichols at UNC-Chapel Hill (formerly Purdue University) for potential use in
CE-LAD
Synthetic hallucinogen
14. Braden MR, Parrish JC, Naylor JC, Nichols DE. Mol Pharmacol 2006;70:1956–1964. [PubMed: 17000863] Nichols DE, Sassano MF, Halberstadt AL, Klein LM
25I-NBOMe
Pharmaceutical compound
affinity for the serotonin 5-HT1A receptor. The drug was developed by David E. Nichols and colleagues at Purdue University and was subsequently reported by
Bromojimscaline
Chemical compound
MBDB was first synthesized by pharmacologist and medicinal chemist David E. Nichols and later tested by Alexander Shulgin and described in his book, PiHKAL:
MBDB
Chemical compound
January 2026. Lovenberg TW, Brewster WK, Mottola DM, Lee RC, Riggs RM, Nichols DE, Lewis MH, Mailman RB (1989). "Dihydrexidine, a novel selective high
Dihydrexidine
Concept in pharmacology
agonists are associated with hallucinogenic effects. According to David E. Nichols, "Discussions over the years with many colleagues working in the pharmaceutical
Antitarget
Pharmaceutical compound
4-dimethylazetidide (LA-Az, LSZ, or LA-Azetidide). The laboratory of David E. Nichols and colleagues synthesized LA-Aziridine in the 1980s while studying
LA-Aziridine
American chemist and recreational drug explorer (1925–2014)
Jason Wallach (guest), David E. Nichols (guest), Rick Doblin (guest), Raffi Kahatchadorourian (guest), Wendy Tucker (guest), David Meyer (guest), Paul Daley
Alexander_Shulgin
Class of chemical compounds
The serotonin-releasing 2-aminoindanes like MDAI were developed by David E. Nichols and colleagues at Purdue University and were first described in 1990
Substituted_2-aminoindane
Pharmaceutical compound
CT-5126 UH-232 Nichols DE (2018). "Chemistry and Structure-Activity Relationships of Psychedelics". In Halberstadt AL, Vollenweider FX, Nichols DE (eds.).
DOM-AT
Pharmaceutical compound
serotonin 5-HT2A and 5-HT2C receptors than tomscaline. It was developed by David E. Nichols and colleagues at Purdue University and was subsequently reported by
Bromotomscaline
Hallucinogenic class of psychoactive drug
uses the more common, narrower definition of psychedelic. David E. Nichols and Charles D. Nichols have criticized the expansion of the definition of the
Psychedelic_drug
Chemical compound
and analogue of lysergic acid diethylamide (LSD) first described by David E. Nichols and colleagues in the 1980s. According to Alexander Shulgin in his
BU-LAD
Chemical compound
with amphetamine. MDAI was developed in the 1990s by a team led by David E. Nichols at Purdue University. It has been encountered as a designer drug and
MDAI
Pharmaceutical compound
LSD metabolites like 14-hydroxy-LSD remain unidentified. As of 2016, David E. Nichols noted that the pharmacology of hydroxylated LSD metabolites, including
14-Hydroxy-LSD
United States Army general (1907–2000)
Kenneth David Nichols CBE (13 November 1907 – 21 February 2000) was an officer in the United States Army, and a civil engineer who worked on the secret
Kenneth_Nichols
Chemical compound (psychedelic drug)
1976. Subsequently, it was further studied by Andrew J. Hoffman and David E. Nichols in 1985. Alexander Shulgin described the effects of AL-LAD in humans
AL-LAD
Chemical compound
family developed in the 1990s by a team at Purdue University led by David E. Nichols. It appears to act as a serotonin releasing agent based on rodent drug
MDAT
Chemical compound
of the 2-aminoindane family developed in the 1990s by a team led by David E. Nichols at Purdue University. It acts as a non-neurotoxic serotonin releasing
MDMAI
1954 book by Aldous Huxley
Dunaway, David King (1989) p. 300 Dunaway, David King (1989) p. 327 Dunaway, David King (1989) p. 298 Dunaway, David King (1989) p. 330 Dunaway, David King
The_Doors_of_Perception
Chemical compound
similarities with pertines like oxypertine. 5-MeO-T-NBOMe was described by David E. Nichols and colleagues in 2015. It was encountered online as a novel designer
5-MeO-T-NBOMe
Pharmaceutical compound
It is closely related to proscaline and was first synthesized by David E. Nichols and colleagues. The drug is taken orally. In his book PiHKAL (Phenethylamines
Isoproscaline
American actor and director (born 1980)
Walking Dead. Nichols was born in Ann Arbor, Michigan, and moved to Austin, Texas before his first birthday. He was named after the Austin Nichols distilling
Austin_Nichols
Pharmaceutical compound
AMMT was first described in the scientific literature by David Lance Roman and David E. Nichols and colleagues at Purdue University by 2004. Cyclized phenethylamine
1-Aminomethyl-6-methoxytetralin
1-Aminomethyl-6-methoxytetralin
American behavioral pharmacologist
use, such as treatment of autistic spectrum disorders. Along with David E. Nichols and others, Fantegrossi was featured as one of the major academic psychedelic
William_E._Fantegrossi
Chemical compound
1-Aminomethyl-5-methoxyindane (AMMI), is a drug developed by a team led by David E. Nichols at Purdue University, which acts as a selective serotonin releasing
1-Aminomethyl-5-methoxyindane
Pharmaceutical compound
phenethylamine and 2C families that was developed by Daniel Trachsel and David E. Nichols and colleagues. The drug's affinity (Ki) for the rat serotonin 5-HT2A
2C-Ph
Jason Wallach (guest), David E. Nichols (guest), Rick Doblin (guest), Raffi Kahatchadorourian (guest), Wendy Tucker (guest), David Meyer (guest), Paul Daley
List of psychedelic documentaries
List_of_psychedelic_documentaries
Pharmaceutical compound
DOM-CR. DOM-AI was first described in the scientific literature by David E. Nichols and colleagues in 1974. Other cyclized analogues of DOM and related
DOM-AI
Pharmaceutical compound
in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007. The compound without the 4-bromo substitution
2CLisaB
Pharmaceutical compound
discovered. They were first described in the scientific literature by David E. Nichols and colleagues in 1985. SKF-89,145 "Delving into the Latest Updates
SKF-89626
Pharmaceutical compound
000-fold lower in comparison) in the isolated rat uterus. In studies by David E. Nichols and colleagues, iso-LSD fully substituted for LSD in rodent drug discrimination
Iso-LSD
Pharmaceutical compound
1961 (filed in 1956). The drug's pharmacology was later studied by David E. Nichols and colleagues. Substituted lysergamide Lysergic acid isopropylamide
Lysergic_acid_tert-butylamide
Pharmaceutical compound
in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007. Substituted methoxyphenethylamine Cyclized
2CBecca
Pharmaceutical compound
5-MeO-T-NB3OMe was first described in the scientific literature by David E. Nichols and colleagues in 2015. It is not a controlled substance in Canada
5-MeO-T-NB3OMe
Chemical compound
first observed in 1976 and were described by Alexander Shulgin and David E. Nichols and colleagues by 1978. 5-MeO-AMT is considered a Schedule 9 prohibited
5-MeO-AMT
Psychedelic drug
phenethylamine and 2C families. It was first synthesized in the laboratory of David E. Nichols. Later, it was tested in humans and its psychedelic effects were confirmed
2C-TFM
Chemical compound
MDMA in animals. 5-IAI was developed in the 1990s by a team led by David E. Nichols at Purdue University. It was encountered as a novel recreational designer
5-IAI
Chemical compound
synthesized by Jason C. Parrish as part of the research team led by David E. Nichols. In studies in vitro, it was found to be slightly more potent than
ETFELA
Psychedelic phenthylamine drug
further described by Otakar Leminger in 1972. Then, it was studied by David E. Nichols and colleagues, who prepared a series of mescaline analogues that included
Escaline
Pharmaceutical compound
described in the scientific literature by Nicholas Cozzi, a student of David E. Nichols, by 1994. Cyclized phenethylamine 2CB-Ind 2CB7 6-AB CT-5126 Lorcaserin
TFMBOX
Pharmaceutical compound
in the scientific literature by Michael Robert Braden of the lab of David E. Nichols at Purdue University in 2007. Substituted methoxyphenethylamine Cyclized
2CJP
Stimulant designer drug
replaced with a methylene instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic
6-APDB
American drug researcher
Gallimore Luis Eduardo Luna Terence McKenna Dennis McKenna Jeremy Narby David E. Nichols Jonathan Ott Benny Shanon DMT: The Spirit Molecule, a documentary based
Rick_Strassman
Chemical compound
derivative of 3,4-methylenedioxyamphetamine (MDA), which was developed by David E. Nichols and coworkers, in the course of research to determine the bulk tolerance
3,4-Ethylidenedioxyamphetamine
3,4-Ethylidenedioxyamphetamine
American domestic terrorist (born 1955)
McVeigh, Nichols, and Fortier were the only defendants indicted in the bombing. Nichols denied his involvement in the plot until 2004. Nichols's mother
Terry_Nichols
Chemical compound
It was subsequently investigated in more detail by the team led by David E. Nichols at Purdue University in the 1990s. The main use for this drug has been
MiPLA
Chemical compound
a methylene bridge instead. 5-APDB was developed by a team led by David E. Nichols at Purdue University as part of their research into non-neurotoxic
5-APDB
Chemical compound
agonist at the dopamine D1 receptor. Gulwadi AG, Korpinen CD, Mailman RB, Nichols DE, Sit SY, Taber MT (February 2001). "Dinapsoline: characterization of
Dinapsoline
Class of chemical compounds
well as in his literature reviews. They have also been studied by David E. Nichols and Daniel Trachsel, among other researchers. A closely related group
Scaline
Chemical compound
preclinical pharmacology was studied and described by Andrew J. Hoffman and David E. Nichols in 1985. ETH-LAD's properties and effects in humans were assessed by
ETH-LAD
Pharmaceutical compound
Structure to Function). It was originally synthesized and studied by David E. Nichols and colleagues at Purdue University, who provided information about
Tomscaline
Psychoactive drug taken by mouth
by 1978. It was described in a paper authored by Alexander Shulgin, David E. Nichols, and other colleagues. As an enantiomer of MDMA, (R)-MDMA is a Schedule
(R)-MDMA
1967 social phenomenon in San Francisco
portal Counterculture of the 1960s 1967 in music Acid rock Allen Ginsberg David Peel Deadhead Central Park be-ins Commune Grateful Dead Hippies Jefferson
Summer_of_Love
Music genre based on 1960s psychedelic music
contra-distinct to the sing-song filigree of British psychedelia". According to David Luhrssen and Michael Larson's book Encyclopedia of Punk Rock and New Wave
Neo-psychedelia
Psychedelic drug
scientific literature by Thomas McLean and colleagues of the lab of David E. Nichols at Purdue University in 2006. It was encountered as a novel designer
TCB-2
Pharmaceutical compound
many others. 2C-T was first described in the scientific literature by David E. Nichols and Alexander Shulgin in 1976. It was described in greater detail by
2C-T
Chemical compound
hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT2A receptor with a Ki
25I-NBMD
Pharmaceutical compound
not produce the head-twitch response. 14-Methyl-LSD was described by David E. Nichols and colleagues in association with 2A Biosciences as a key compound
14-Methyl-LSD
Pharmaceutical compound
colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s. It is not a controlled substance in Canada
IPLA
Pharmaceutical compound
RS130-180 was developed via structural modification of ZINC000341335936 by David E. Nichols and colleagues. 25-NB List of miscellaneous 5-HT2A receptor agonists
RS130-180
Music genre
Brown instrumental album Sho Is Funky Down Here, directed by bandleader David Matthews, explored "fuzzy" psychedelic funk. Jazz musician Miles Davis,
Psychedelic_funk
Pharmaceutical compound
the lab of David E. Nichols at Purdue University by 1987. It was subsequently further described by a group of researchers that included Nichols and other
MAL-LAD
American songwriter and composer
David Wingo is an American film and television composer. He is known for his collaborations with directors David Gordon Green, Jeff Nichols, and Jeff
David_Wingo
American actress (1932–2022)
"Nichelle" Nichols was born the third of six children on December 28, 1932, in Robbins, Illinois, a suburb of Chicago, to Samuel Earl Nichols, a factory
Nichelle_Nichols
Chemical compound
but mostly publicised through research conducted by the team led by David E. Nichols at Purdue University. It is a structural isomer of LSD, with the two
Lysergic_acid_2-butylamide
Pharmaceutical compound
Shulgin in 2011, the effects of F in humans are unknown. However, David E. Nichols reported in 1981, via personal communication with Shulgin and M. Trampota
F_(psychedelic)
Pharmaceutical compound
colleagues by 1955. Subsequently, it was studied in more detail by David E. Nichols and colleagues in the 1990s and thereafter. Substituted lysergamide
DiPLA
Chemical compound
N-(3-pentyl)lysergamide, is an analogue of LSD originally researched by David E. Nichols and colleagues at Purdue University. It has similar binding affinity
Lysergic_acid_3-pentylamide
Pharmaceutical compound
Subsequent research by David E. Nichols found that DCLA did not show LSD-like effects in animal drug discrimination tests. According to Nichols, the simplest ergoline
Descarboxylysergic_acid
Pharmaceutical compound
first described in the scientific literature by Daniel Trachsel and David E. Nichols and colleagues in 2009. It is a controlled substance in Canada under
2C-BI-8
Pharmaceutical compound
described. 2-LSP was first described in the scientific literature by David E. Nichols and colleagues by 1995. Substituted lysergamide Lysergic acid 2-butylamide
Lysergic_acid_2-pentylamide
Chemical compound
developed by the team led by J. E. Macor and colleagues in 1992. It was subsequently investigated by the team led by David E. Nichols from Purdue University in
5-MeO-MPMI
Pharmaceutical compound
Mescaline-FLY was first described in the scientific literature by the lab of David E. Nichols and colleagues by 1995. Mescaline-FLY is not a controlled substance
Mescaline-FLY
Chemical compound
described in the scientific literature by Jose Juncosa of the lab of David E. Nichols at Purdue University in 2011. DMBMPP is not an explicitly controlled
DMBMPP
travel, tourism, insurance
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
DAVID E-NICHOLS
travel, tourism, insurance